Volume 24, Number 5—May 2018
Dispatch
Heartland Virus and Hemophagocytic Lymphohistiocytosis in Immunocompromised Patient, Missouri, USA
Table 1
Test type |
Reference range |
4 mo before symptom onset |
Post–symptom onset day |
||||
6 |
8 |
11 |
18 |
20 |
|||
Leukocyte count, × 103 cells/µL | 3.8–9.8 | 13.7 | 5.8 | 5.00 | 1.60 | 0.2 | NR |
Absolute neutrophil count, cells/µL | 1,800–6,600 | 7,400 | 5,000 | 4,100 | 1,200 | <100 | NR |
Absolute lymphocyte count, cells/µL | 1,200–3,300 | 3,300 | 700 | 500 | 400 | 100 | NR |
Hemoglobin, g/dL | 13.8–17.2 | 12.1 | 11.8 | 10.5 | 7.1 | 7.0 | NR |
Hematocrit, % | 40.7–50.3 | 36.4 | 32.5 | 30.5 | 21.2 | 21.2 | NR |
Platelets, × 103/µL | 140–440 | 202 | 76 | 42 | 47 | 19 | NR |
International normalized ratio | 0.90–1.20 | 1.06 | 1.0 | 1.19 | 1.15 | 1.47 | NR |
Partial thromboplastin time, s | 25.0–37.0 | 46 | 40 | 53.1 | 56.6 | 39.7 | 38.3 |
Lactate dehydrogenase, units/L | 100–250 | NR | 422 | 641 | 3040 | NR | NR |
Haptoglobin, mg/dL | 27–220 | NR | NR | 208 | 227 | NR | NR |
Ferritin, ng/mL | 22–322 | NR | NR | 6,308 | 53,666 | NR | NR |
Fibrinogen, mg/dL | 170–400 | NR | NR | NR | 215 | NR | NR |
Sodium, mmol/L | 135–145 | 139 | 128 | 141 | 141 | 138 | 136 |
Potassium, mmol/L | 3.3–4.9 | 4.0 | 5.1 | 5.9 | 5.1 | 5.5 | 4.8 |
Carbon dioxide, mmol/L | 22–32 | 27 | 13 | 15 | 16 | 21 | 25 |
Blood urea nitrogen, mg/dL | 8–25 | 16 | 90 | 63 | 94 | 60 | 50 |
Creatinine, mg/dL | 0.70–1.30 | 1.31 | 3.38 | 1.75 | 4.74 | 1.95† | 1.80† |
Troponin I, ng/mL | 0.00–0.03 | 2.55 | 0.76 | 0.27 | NR | NR | NR |
Cholesterol, total, mg/dL | 0–200 | 258 | 115 | NR | NR | NR | NR |
Triglycerides, mg/dL | 0–150 | 426 | 532 | NR | NR | NR | NR |
Aspartate aminotransferase, units/L | 11–47 | 32 | 231 | 147 | 684 | NR | 146 |
Alanine aminotransferase, units/L | 7–53 | 17 | 186 | 112 | 118 | NR | 52 |
Alkaline phosphatase, units/L | 38–126 | 85 | 60 | 65 | 111 | NR | 65 |
Bilirubin, total, mg/dL | 0.3–1.1 | 0.3 | 0.1 | 0.2 | 0.2 | NR | 0.7 |
Bilirubin, direct, mg/dL | 0.0–0.3 | 0.1 | 0.1 | NR | 0.2 | NR | NR |
Amylase, units/L | 28–100 | NR | 234 | NR | NR | NR | NR |
Lipase, units/L | 0–99 | NR | 578 | NR | NR | NR | NR |
pH | 7.35–7.45 | NR | 7.31 | 7.17 | 7.24 | 7.42 | 7.32 |
PaCO2, mm Hg | 35–45 | NR | 21 | 41 | 38 | 36 | 47 |
PaO2, mm Hg | 80–105 | NR | 125 | 93 | 108 | 159 | 96 |
Temperature, °C | 35.5–38.3 | NR | 36.6 | 38.9 | 38.2 | 37.3 | 35.4 |
FiO2 | 0.21 | NR | 0.40 | 0.40 | NR | 0.40 | NR |
*FiO2, fraction of inspired oxygen; NR, not reported; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen.
†On continuous venovenous hemodialysis.
Page created: April 17, 2018
Page updated: April 17, 2018
Page reviewed: April 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.